DOI: 10.4244/EIJ-D-18-00542L

Indexed patent ductus arteriosus size as the prime predictor of post device closure left ventricular dysfunction: does it have any competitors?

Naveen Garg, MD, DM; Krishnarpan Chatterjee*, MD, DNB

In their study, Kiran et al propose the indexed patent ductus arteriosus (PDA) size at the pulmonary artery end as a simple predictor of post-procedural left ventricular (LV) dysfunction in those with baseline normal LV function1. Whilst we agree with the authors’ observation that the size of the PDA is an important prognostic marker, it is not uncommon to find a PDA where the diameter at the pulmonary artery end is not the minimum diameter. In such cases, the minimum PDA diameter indexed to body surface area may be an appropriate measure. Although this is by far the largest published group and a commendable effort, we believe that methodological gaps prevent this study from establishing the indexed PDA size as a more robust predictor.

The authors consider a univariate model and show a significant correlation between indexed PDA size and post-procedural LV dysfunction. We are curious to know whether this would stand up as an independent predictor in a multivariate model. Previous studies have been limited by their small sample size but have made some important observations. Gupta et al showed that baseline LV ejection fraction, LV end-diastolic volume and PDA diastolic gradient predicted post-procedural LV dysfunction2. Jeong et al showed that device closure should be carried out before left ventricular ejection fraction (LVEF) decreases to less than 62% in order to have a normal post-closure EF3. Pre-closure global longitudinal strain (GLS) predicted LV dysfunction measured as increased myocardial performance index (MPI)4. A larger left to right shunt and higher pulmonary artery pressure pre-closure is also associated with LV dysfunction estimated by fractional shortening5. Both LVEF and MPI are load-dependent measures of LV function. During “afterload mismatch” in the immediate post-closure period, isovolumic acceleration (IVA) would be a better measure of LV function. Age at the time of procedure is also a plausible predictor of LV dysfunction2.

Including all these variables along with indexed PDA size in a multivariate model would allow us to extract maximum inference from the large study population in this article. Distribution of the baseline variables across the four pre-specified groups should also be made available.

We hope that our suggestions would help in interpreting the study data further and possibly generate further new hypotheses.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Volume 14 Number 18
Apr 5, 2019
Volume 14 Number 18
View full issue


Key metrics

Suggested by Cory

Letter to the editor

10.4244/EIJ-D-25-01218 Feb 16, 2026
Letter: Beyond frame expansion: interpreting the implications of routine post-dilatation
Sturla M et al
free

CLINICAL RESEARCH

10.4244/EIJ-D-15-00238 Apr 20, 2017
Are the AMPLATZER Duct Occluder II Additional Sizes devices dedicated only for smaller children?
Fiszer R et al
free

Letter to the editor

10.4244/EIJ-D-26-00101 Apr 20, 2026
Letter: Transcatheter paravalvular leak closure – insights on selection criteria, imaging, and comparative outcomes
Güner A et al
free

Clinical research

10.4244/EIJ-D-23-00517 Dec 18, 2023
Changes in post-PCI physiology based on anatomical vessel location: a DEFINE PCI substudy
Matsumura M et al
free

Editorial

10.4244/EIJ-E-25-00044 Oct 6, 2025
Just tap it in... stent optimisation in TAVI
Mylotte D and Thaddeus Soh B
free
Trending articles
334.45

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
83.8

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
37.95

State-of-the-Art

10.4244/EIJ-D-24-00195 Apr 7, 2025
Percutaneous coronary intervention for calcified and resistant lesions
Pesarini G et al
free
33.05

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
28.6

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
28.6

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
19.25

State-of-the-Art

10.4244/EIJ-D-24-00387 Jul 21, 2025
Advances in coronary imaging of atherosclerotic plaques
Garcia-Garcia H et al
free
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved